ArticleBreast cancer (Tokyo, Japan)2023

Detection of high-risk patients resistant to CDK4/6 inhibitors with hormone receptor-positive HER2-negative advanced and metastatic breast cancer in Japan (KBCSG-TR-1316).

Manabu Futamura et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.